AAAAAA

   
Results: 1-10 |
Results: 10
Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix
Authors: Connor, BA Phair, J Sack, D McEniry, D Hornick, R Banerjee, D Jensen, E Kuter, B
Citation: Ba. Connor et al., Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix, CLIN INF D, 32(3), 2001, pp. 396-401
Thrush and fever as markers of immune competence in the era of highly active antiretroviral therapy
Authors: Skolasky, RL Phair, J Detels, R Riddler, S Margolick, J Jacobson, LP
Citation: Rl. Skolasky et al., Thrush and fever as markers of immune competence in the era of highly active antiretroviral therapy, AIDS RES H, 17(14), 2001, pp. 1311-1316
Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy
Authors: Tebas, P Henry, K Nease, R Murphy, R Phair, J Powderly, WG
Citation: P. Tebas et al., Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy, AIDS, 15(5), 2001, pp. 591-599
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.
Authors: Gao, XJ Nelson, GW Karacki, P Martin, MP Phair, J Kaslow, R Goedert, JJ Buchbinder, S Hoots, K Vlahov, D O'Brien, SJ Carrington, M
Citation: Xj. Gao et al., Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS., N ENG J MED, 344(22), 2001, pp. 1668-1675
Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts
Authors: Tarwater, PM Mellors, J Gore, ME Margolick, JB Phair, J Detels, R Munoz, A
Citation: Pm. Tarwater et al., Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts, AM J EPIDEM, 154(7), 2001, pp. 675-681
Association of race and gender with HIV-1 RNA levels and immunologic progression
Authors: Anastos, K Gange, SJ Lau, B Weiser, B Detels, R Giorgi, JV Margolick, JB Cohen, M Phair, J Melnick, S Rinaldo, CR Kovacs, A Levine, A Landesman, S Young, M Munoz, A Greenblatt, RM
Citation: K. Anastos et al., Association of race and gender with HIV-1 RNA levels and immunologic progression, J ACQ IMM D, 24(3), 2000, pp. 218-226
AIDS onset at high CD4(+) cell levels is associated with high HIV load
Authors: Hennessey, KA Giorgi, JV Kaplan, AH Visscher, BR Gange, S Margolick, JB Riddler, S Phair, J Detels, R
Citation: Ka. Hennessey et al., AIDS onset at high CD4(+) cell levels is associated with high HIV load, AIDS RES H, 16(2), 2000, pp. 103-107
Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma
Authors: Jacobson, LP Jenkins, FJ Springer, G Munoz, A Shah, KV Phair, J Zhang, ZF Armenian, H
Citation: Lp. Jacobson et al., Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma, J INFEC DIS, 181(6), 2000, pp. 1940-1949
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence
Authors: Abrams, D Allan, D Antunes, F Breckenridge, A Bruun, J Cameron, W Carbon, C Chalmers, I Chang, H Chodakewitz, J Clendenin, N Clumeck, N Collier, A Collins, G Cooper, E Cooper, D Danner, S D'Aquila, R DeGruttola, V DeMasi, R Dee, L Deyton, L Dixon, D Farthing, C Feinberg, J Fischl, M Flepp, M Gartland, M Gatell, J Gazzard, B Goebel, F Gotzsche, P Gringeri, A Hall, D Hamilton, J Hammer, S Hartigan, P Heath-Chiozzi, M Henry, K Hill, A Hirschel, B Ioannidis, J Kahn, J Katlama, C Katzenstein, D Killen, J King, E de Loes, SK Kravcik, S Lange, J Leavitt, R Leonard, J Maeland, A Mannucci, P Mathiesen, L McDade, H Meibohn, A Melander, H Merigan, T Mulder, J Myers, M Neaton, J Nessling, M Perrin, L Pettinelli, C Phair, J Phillips, A Pinching, A Poppa, A Power, L Reiss, P Richman, D Rooney, J Rousseau, F Rutherford, G Salgo, M Sandstrom, E Saravolatz, L Savidge, G Schnittman, S Schooley, R Seligmann, M Simberkoff, M Skowron, G Slade, P Smith, D Smith, RP Soriano, V Stanley, K Stingl, G Stoffels, P Struthers, L Tierney, C Thompson, M Van der Broeck, R Van Leeuven, R Van Weverling, G Veenstra, J Vella, S Volberding, P Weber, J Winslow, D Yeni, P Yeo, J Dormont, J Sande, M Weller, I Babiker, A Collins, R Darbyshire, J Duncan, W Foulkes, M Hughes, M Peto, R Peto, T Walker, S
Citation: D. Abrams et al., Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence, LANCET, 353(9169), 1999, pp. 2014-2025
Does use of potent antiretroviral therapy differ by health care setting? Reply
Authors: Detels, R Munoz, AH Phair, J
Citation: R. Detels et al., Does use of potent antiretroviral therapy differ by health care setting? Reply, J AM MED A, 281(18), 1999, pp. 1697-1697
Risultati: 1-10 |